Published :
Tables : 19
Figures : 31
Category : Healthcare
No. of Pages : 220
Report Code : HC-1094
Off-Label Anticancer Drugs Market Introduction Off-label is also called non-approved or unapproved use of a drug. There are three conditions under which a drug can be considered as off-label: (i) As no steps have been taken to extend the approval although efficacy evidence is available (ii) As these drugs come under the ‘grey zone’ category of evidence- based medicine, within which it is difficult to reach high-level evidence even for likely effective treatments especially in rare disease cases (iii) As these drugs are ineffective or it is irrational to believe it as effective The issue of off label drugs market is more prominent in the field of oncology than in other areas. One of the major reasons is the types of cancer. An anticancer drug assigned for a particular type of cancer can also be used for other cancer types. In actuality, many anticancer drugs that are widespread don’t get the label for all the symptoms for which they can be used effectively for treatment. Persistent demand of anti-neoplastic drugs in better management of cancer fuelled the demand of off-label drugs. It is most common among cancer therapies due to limited availability of approved drugs for treatment. They are proven effective for many indications and in combination therapies when compared to monotherapy. Further, rising cancer prevalence among general population fuelled the growth of the market. Along with this, changing regulatory conditions to support manufacturers in the rapid advancement of technologies led to robust growth. It is legal in the US for off-label drug use and offers reimbursements for cancer treatment. Additionally, growing research activities to expand the disease indication fuelled the investments. All these factors led to the robust growth of the market during the forecast period. Global market is dominated by North America due to supportive regulatory policies and high adoption among the physicians. North America is dominated by the US and it is expected to remain dominant same throughout the forecast period. It is followed by the European region and it is dominated by the UK, Germany, and France. European regulatory bodies restrict the off-label drug use but there is high adoption among the general physicians. It is followed by the Asia Pacific and Latin America regions are fast growing regions due to increasing adoption. They are expected accounts for 25% share of the global market. Rest of World accounts the small fraction of the global market and expected to remain the same throughout the forecast period. Off-Label Anticancer Drugs market players are Pfizer Inc, Roche Holding, Merck Co & Inc, Novartis AG, Sanofi S.A., Gilead, J&J and others Off-Label Anticancer Drugs Market Segmentation By Indications Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others By End User Hospitals Pharmacies By Region North America Latin America Europe Asia Pacific Rest of the World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global Off-Label Anticancer Drugs Market by Indications, by End-User, and by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Off-Label Anticancer Drugs Market Introduction
Off-label is also called non-approved or unapproved use of a drug. There are three conditions under which a drug can be considered as off-label: (i) As no steps have been taken to extend the approval although efficacy evidence is available (ii) As these drugs come under the ‘grey zone’ category of evidence- based medicine, within which it is difficult to reach high-level evidence even for likely effective treatments especially in rare disease cases (iii) As these drugs are ineffective or it is irrational to believe it as effective
The issue of off label drugs market is more prominent in the field of oncology than in other areas. One of the major reasons is the types of cancer. An anticancer drug assigned for a particular type of cancer can also be used for other cancer types. In actuality, many anticancer drugs that are widespread don’t get the label for all the symptoms for which they can be used effectively for treatment.
Persistent demand of anti-neoplastic drugs in better management of cancer fuelled the demand of off-label drugs. It is most common among cancer therapies due to limited availability of approved drugs for treatment. They are proven effective for many indications and in combination therapies when compared to monotherapy. Further, rising cancer prevalence among general population fuelled the growth of the market. Along with this, changing regulatory conditions to support manufacturers in the rapid advancement of technologies led to robust growth. It is legal in the US for off-label drug use and offers reimbursements for cancer treatment. Additionally, growing research activities to expand the disease indication fuelled the investments. All these factors led to the robust growth of the market during the forecast period.
Global market is dominated by North America due to supportive regulatory policies and high adoption among the physicians. North America is dominated by the US and it is expected to remain dominant same throughout the forecast period. It is followed by the European region and it is dominated by the UK, Germany, and France. European regulatory bodies restrict the off-label drug use but there is high adoption among the general physicians. It is followed by the Asia Pacific and Latin America regions are fast growing regions due to increasing adoption. They are expected accounts for 25% share of the global market. Rest of World accounts the small fraction of the global market and expected to remain the same throughout the forecast period.
Off-Label Anticancer Drugs market players are Pfizer Inc, Roche Holding, Merck Co & Inc, Novartis AG, Sanofi S.A., Gilead, J&J and others
Off-Label Anticancer Drugs Market Segmentation
By Indications
By End User
By Region
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global Off-Label Anticancer Drugs Market by Indications, by End-User, and by Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Introduction Scope and Objective Assumptions and Acronyms Forecast Factors Research Methodology Executive Summary Industry Cluster Analysis Competition Matrix Strategies Recommendations Market Definition Report Scope (Inclusions & Exclusions) Market Segmentation Global Off-Label Anticancer Drugs Market Overview Global Off-Label Anticancer Drugs Market Revenue (USD Mn) Key Inclusions Porter’s Five Force analysis Market Dynamics Industry Trends Regulatory Guidelines Opportunities in Off-Label Anticancer Drugs Competition Dynamics Company Share Analysis (2019) Top 10 Product Pricing by Region Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2019-2027 by Indication Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027 Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2019-2027 by End User Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027 Hospitals Pharmacies Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2019-2027 by Region Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Region,2027 North America Latin America Europe Asia Pacific Rest of world North America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2027 US Canada Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027 Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027 Hospitals Pharmacies Latin America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2027 Brazil Mexico Argentina Rest of Latin America Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027 Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027 Hospitals Pharmacies Europe America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2027 Germany France Spain UK Russia Poland Rest of Europe Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027 Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027 Hospitals Pharmacies Asia Pacific America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2027 Emerging Asia China India ASEAN-5 Rest of Emerging Asia Japan Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027 Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027 Hospitals Pharmacies Rest of World America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2027 Middle East South Africa North Africa Rest of World Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027 Lung Cancer Breast Cancer Prostate Cancer Skin Cancer Bladder Cancer Others Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027 Hospitals Pharmacies Company Profiles Competition Landscape Global Company Share (USD Mn) Overview, 2019 Company Profiles Pfizer Inc Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Roche Holding Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Merck Co & Inc Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Novartis AG Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Sanofi S.A. Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Research Sources & Primary Verbati
Introduction
Scope and Objective
Assumptions and Acronyms
Forecast Factors
Research Methodology
Executive Summary
Industry Cluster Analysis
Competition Matrix
Strategies Recommendations
Market Definition
Report Scope (Inclusions & Exclusions)
Market Segmentation
Global Off-Label Anticancer Drugs Market Overview
Global Off-Label Anticancer Drugs Market Revenue (USD Mn)
Key Inclusions
Porter’s Five Force analysis
Market Dynamics
Industry Trends
Regulatory Guidelines
Opportunities in Off-Label Anticancer Drugs
Competition Dynamics
Company Share Analysis (2019)
Top 10 Product Pricing by Region
Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2019-2027 by Indication
Key Market Findings
Long Term ROI Segments
Revenue Opportunity Influencing Factors
Market Revenue (USD Mn) Assessment and Forecast by Indication, 2019-2027
Lung Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Bladder Cancer
Others
Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2019-2027 by End User
Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2027
Hospitals
Pharmacies
Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2019-2027 by Region
Market Revenue (USD Mn) Assessment and Forecast by Region,2027
North America
Latin America
Europe
Asia Pacific
Rest of world
North America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027
Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2027
US
Canada
Latin America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027
Brazil
Mexico
Argentina
Rest of Latin America
Europe America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027
Germany
France
Spain
UK
Russia
Poland
Rest of Europe
Asia Pacific America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027
Emerging Asia
China
India
ASEAN-5
Rest of Emerging Asia
Japan
Rest of World America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2019-2027
Middle East
South Africa
North Africa
Rest of World
Company Profiles
Competition Landscape
Global Company Share (USD Mn) Overview, 2019
Pfizer Inc
Corporate Overview
Financial Performance
Peer Comparison & 3C marketing equation
Company Strategy & Channel Management
Roche Holding
Merck Co & Inc
Novartis AG
Sanofi S.A.
Research Sources & Primary Verbati
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics